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ABSTRACT
Since the discovery of the C9orf72 repeat expansion 
as the most common genetic cause of frontotemporal 
dementia (FTD) and amyotrophic lateral sclerosis, it has 
increasingly been associated with a wider spectrum 
of phenotypes, including other types of dementia, 
movement disorders, psychiatric symptoms and slowly 
progressive FTD. Prompt recognition of patients with 
C9orf72- associated diseases is essential in light of 
upcoming clinical trials. The striking clinical heterogeneity 
associated with C9orf72 repeat expansions remains 
largely unexplained. In contrast to other repeat 
expansion disorders, evidence for an effect of repeat 
length on phenotype is inconclusive. Patients with 
C9orf72- associated diseases typically have very long 
repeat expansions, containing hundreds to thousands 
of GGGGCC- repeats, but smaller expansions might 
also have clinical significance. The exact threshold at 
which repeat expansions lead to neurodegeneration is 
unknown, and discordant cut- offs between laboratories 
pose a challenge for genetic counselling. Accurate and 
large- scale measurement of repeat expansions has been 
severely hindered by technical difficulties in sizing long 
expansions and by variable repeat lengths across and 
within tissues. Novel long- read sequencing approaches 
have produced promising results and open up avenues 
to further investigate this enthralling repeat expansion, 
elucidating whether its length, purity, and methylation 
pattern might modulate clinical features of C9orf72- 
related diseases.
INTRODUCTION
A repeat expansion in C9orf72 is the most common 
genetic cause of frontotemporal dementia (FTD) 
and amyotrophic lateral sclerosis (ALS) world-
wide.1 2 Besides typical features of FTD and ALS, the 
expansion is increasingly associated with a broader 
range of symptoms, including psychiatric manifes-
tations and parkinsonism, and has also been iden-
tified in patients with no known family history for 
neurodegenerative disease.3 4 Early recognition of 
C9orf72- related illnesses is becoming increasingly 
important with the advent of disease- modifying 
therapeutic trials.
The substantial clinical heterogeneity observed in 
C9orf72 expansion carriers, in terms of phenotype, 
age at symptom onset and rate of disease progres-
sion, suggests that there are underlying disease 
modifiers which may serve as prognostic factors 
as well as targets for therapeutic interventions. 
Drawing on evidence from other neurodegenerative 
repeat expansion disorders, including Hunting-
ton’s disease (HD), several spinocerebellar ataxias 
and myotonic dystrophy,5 an explanation for this 
heterogeneity has primarily been sought in repeat 
length. Studies relating C9orf72 repeat length to 
clinical features have produced inconsistent results, 
but they have been hampered by technical difficul-
ties in detecting and sizing expansions.6–8
In this review, we present an overview of the 
clinical spectrum associated with C9orf72 repeat 
expansions. We then discuss the role of repeat 
length in relation to the C9orf72 phenotype. 
Finally, we provide an in- depth examination of 
the advantages and limitations of current and 
novel methods to identify and measure repeat 
expansions.
GENETICS AND PATHOPHYSIOLOGY OF 
C9ORF72 REPEAT EXPANSIONS
The C9orf72 repeat expansion is located in a 
non- coding region and consists of an expanded 
GGGGCC- repeat. Healthy individuals commonly 
carry less than 30 repeats, whereas those with 
C9orf72- associated diseases usually have several 
hundreds to thousands of repeats.1 2 9 The exact 
function of the C9orf72 protein is unknown, but it is 
thought to play a role in autophagy and endosomal 
trafficking. Three possibly coexisting disease mech-
anisms have been proposed: (1) haploinsufficiency 
due to reduced expression of C9orf72 from the 
expanded allele, (2) formation of repeat- containing 
RNA foci through bidirectional transcription of 
the expansion and (3) production of aggregation- 
prone dipeptide repeat (DPR) proteins via repeat- 
associated non- ATG translation. These mechanisms 
have in turn been associated with a wide range of 
downstream cellular defects, such as alterations in 
stress granules, proteostasis, nucleocytoplasmic 
and vesicular transport, mitochondrial function 
and immunity.10 11 Each disease mechanism alone 
might not be sufficient to cause neurodegeneration, 
and a synergistic model in which C9orf72 loss- of- 
function exacerbates gain- of- function mechanisms 
has been proposed. A better understanding of their 
relative contributions across various disease stages 
is essential in order to determine viable treatment 
targets. Promising therapeutic strategies currently 
being researched include small molecules and 
gene- silencing tools that inhibit C9orf72 transcrip-
tion, antisense oligonucleotides that bind to and 
inactivate repeat- containing RNA, antibody- based 
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approaches to inhibit accumulation of DPR proteins, and 
targeting downstream cellular defects.10 11
Pathologically, C9orf72- related diseases are characterised by 
cytoplasmic aggregates of transactive response DNA- binding 
protein 43 (TDP-43) and p62- positive neuronal cytoplasmic 
inclusions containing DPR proteins.1 2 While TDP-43 pathology 
coincides neuroanatomically with affected regions of the central 
nervous system (CNS) in ALS and FTD, DPR proteins gener-
ally do not. Sense and antisense C9orf72 RNA foci are widely 
distributed throughout the CNS in affected expansion carriers.10
EPIDEMIOLOGY OF C9ORF72 REPEAT EXPANSIONS
A C9orf72 expansion is identified in approximately 5%–10% 
of all patients with FTD or ALS, and in up to 30% of patients 
with both diseases.4 12 Collectively, these diseases are referred to 
as c9FTD/ALS. The prevalence varies strongly between ethnic 
groups: the highest rates are found in Caucasians and the lowest 
in Asians.12 The expansion is highly penetrant, with cumulative 
percentages of 90.9%–99.5% by the age of 83. The first symp-
toms usually manifest themselves in the fifth decade, but age at 
onset is highly variable, even within families, and can range from 
20 to 90 years.9 13 14 The initial presentation and disease course 
also vary widely (box 1, table 1); survival after symptom onset 
ranges from 2 months in rapidly progressive ALS to over 30 
years in slowly progressive behavioural variant FTD (bvFTD).14




A C9orf72 expansion is found in 20%–25% of familial and 
6%–8% of apparently sporadic FTD cases (c9FTD).4 12 The 
median age at onset of 57 years is similar to that of FTD without 
a C9orf72 expansion (non- c9FTD),14 15 but survival after 
symptom onset is shorter (7 vs 11 years), even in the absence of 
concomitant ALS. The clinical presentation of c9FTD is usually 
bvFTD, which is characterised by progressive behavioural and 
personality changes, prominent executive functioning deficits 
and relative sparing of other cognitive domains,16 although 
language variants (non- fluent primary progressive aphasia and 
semantic dementia) may also occur (table 1).14 15 Up to 30% of 
c9FTD patients develop concomitant ALS during the course of 
the disease, but routine screening for ALS symptoms in patients 
with c9FTD is not commonly performed.15 c9FTD cannot be 
reliably distinguished on clinical grounds from non- c9FTD. 
However, c9FTD patients may present with atypical signs and 
symptoms and frequently do not fulfil current diagnostic criteria 
for FTD.16 17 First, memory impairment is more common in 
c9FTD and is often the presenting symptom in older subjects, 
which can lead to misdiagnosis of Alzheimer’s disease (AD).18 19 
Second, psychotic symptoms and bizarre, irrational behaviour 
are common in c9FTD.15 Third, some patients have a protracted 
or seemingly non- progressive disease course. Fourth, atrophy 
patterns in c9FTD are highly variable and can include gener-
alised symmetrical cortical atrophy and atrophy of thalamus and 
cerebellum (figure 1, table 1).19
Benign variant FTD
A slowly progressive variant of bvFTD, with isolated neuro-
psychiatric symptoms and minimal cognitive deterioration over 
many years of follow- up, has been described in several C9orf72 
expansion carriers.20 Furthermore, a recent meta- analysis 
showed that 2% of patients with so- called benign variant FTD, 
Box 1 Representative case histories of notable C9orf72 
expansion carriers, highlighting the variability in clinical 
presentation, age at symptom onset and disease course.
Case 1
A middle- aged woman was admitted to the psychiatric ward 
due to severe vital depression and attempted suicide. She had 
experienced a similar episode of depression with psychosis 
2 years previously which was unresponsive to antidepressants 
and eventually treated with electroconvulsive therapy (ECT). 
Before that time, she had no history of psychiatric disease. Her 
mother had exhibited strange social behaviour from her late 
sixties; her maternal grandfather had been diagnosed with 
Alzheimer’s disease. Extensive laboratory testing and brain MR 
imaging were normal; a fluorodeoxyglucose positron emission 
tomography (FDG- PET) scan revealed bilateral temporal 
and mesiofrontal hypometabolism compatible with FTD. Her 
depression was treated successfully with ECT again, but she 
subsequently suffered progressive cognitive decline and was 
admitted to a nursing home 5 years after her first episode of 
depression.
Cases 2 and 3
A man in his thirties presented with a 2- year history of word 
finding difficulties and memory complaints. Family members 
also reported mild behavioural changes. His father had been 
diagnosed with frontotemporal dementia in his seventies and 
several paternal relatives had suffered from amyotrophic lateral 
sclerosis (ALS). MRI of the brain demonstrated mild bilateral 
frontotemporal atrophy, and neuropsychological assessment 
confirmed deficits in language and executive functioning 
domains. Very slow progression occurred over several years 
of follow- up, with behavioural abnormalities such as social 
disinhibition and loss of decorum becoming more noticeable. 
Currently, 10 years after the initial presentation, he is still living 
independently.
His brother presented in his forties with progressive difficulties 
speaking and swallowing since 3 months. He had subsequently 
developed weakness of the left arm and leg. His partner also 
reported increased emotional lability and memory decline. 
Neurological examination revealed a bulbar dysarthria, tongue 
wasting with fasciculations and brisk jaw jerk, as well as mild 
left- sided hemiparesis. Electromyography was compatible with 
ALS, neuropsychological testing showed mild impairments in 
social cognition and executive functioning, and MRI revealed 
moderate, predominantly left- sided frontotemporal atrophy. His 
condition deteriorated rapidly and he died within 9 months of 
symptom onset.
Case 4
A middle- aged man was admitted to the psychiatric ward 
with a 3- month history of somatic delusions. He had become 
convinced that there were foreign bodies inside his abdominal 
organs and refused to eat or drink. There was no history 
of neurodegenerative diseases on the maternal side of his 
family; his paternal family history was unknown. Neurological 
examination at the time did not reveal focal abnormalities 
except positive primitive reflexes and elevated muscle tone. 
Extensive laboratory testing, MR and FDG- PET imaging, and 
electroencephalography were inconclusive. Despite antipsychotic 
medication, the patient deteriorated rapidly into a state of 
catatonia with limb myoclonus, cerebellar ataxia and apnoeas 
Continued
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in whom neuroimaging abnormalities and disease progression 
are lacking, had a C9orf72 expansion.21 The identification of 
expansions in benign variant FTD suggests that it is a neurode-
generative condition in at least a subset and that genetic testing 
should be considered, especially in those with a positive family 
history.
AD and other dementias
C9orf72 expansions have been identified in a small percentage 
(<1%) of clinically diagnosed AD patients in several large 
cohorts.18 22 Most of these cases can probably be attributed 
to misdiagnoses, especially in older patients with memory 
impairment and atypical neuroimaging, and might not reflect 
a causative association between C9orf72 expansions and AD. 
Accordingly, autopsy studies of expansion carriers with a clinical 
diagnosis of AD revealed either isolated FTD pathology, or FTD 
with concomitant AD pathology,23 24 although more patholog-
ical studies are needed to confirm this. Importantly, concomitant 
AD pathology might modulate the clinical phenotype (ie, more 
amnestic features) and thus conceal the existence of a C9orf72 
expansion. Pure AD pathology without FTD pathology reported 
in three expansion carriers possibly reflects incomplete pene-
trance. From a clinical perspective, the presence of C9orf72 
expansions in clinical cohorts of AD highlights the need to 
screen FTD genes in AD patients with a positive family history.22
Genetic screening of large series of Lewy body dementia 
(DLB) patients did not identify C9orf72 expansion carriers, but 
occasionally, carriers may present as DLB mimics or harbour 
DLB copathology.
Box 1 Continued
and required continuous tube feeding. He remained in a 
fluctuating mute catatonic state over the following 2 years.
Table 1 Common clinical presentations of C9orf72 repeat expansion carriers
Clinical presentation Key clinical features Features enriched in C9orf72 expansion carriers*
FTD
  bvFTD  ► Apathy, disinhibition, loss of empathy, perseverative or compulsive behaviour, 
hyperorality and dietary changes
 ► Impairments in executive function, language, social cognition
 ► Frontotemporal atrophy, often asymmetrical
 ► Concomitant motor neuron disease
 ► Psychotic symptoms
 ► Other psychiatric disturbances
 ► Episodic memory impairment
 ► Parkinsonism (usually late stage)
 ► Highly variable neuroimaging, including generalised 
symmetrical cortical, cerebellar or thalamic atrophy
  nfvPPA  ► Non- fluent, effortful speech, speech apraxia, agrammatism
 ► Preserved single- word comprehension
 ► Predominantly left- sided frontotemporal atrophy
  Benign- variant FTD  ► As in bvFTD but lacking disease progression
 ► Neuroimaging (near) normal
 ► Cognitive impairment
Motor neuron disease
  ALS  ► Asymmetric limb weakness, dysphagia, dysarthria, pseudobulbar affect
 ► Upper and lower motor neuron signs spreading to multiple regions
 ► Cognitive/behavioural abnormalities, bvFTD
 ► Cognitive/behavioural abnormalities, bvFTD
 ► Bulbar onset
 ► Atrophy of non- motor frontal cortical areas, basal 
ganglia
Psychiatric
 ► Hallucinations and delusions, mood disorders, obsessive- compulsive disorder, 
catatonia, anxiety disorders, suicidality
 ► Late onset (age >40 years)
 ► Cognitive deterioration
 ► Psychosis, somatic delusions
 ► Prominent cerebral or cerebellar atrophy
*Family history of neurodegenerative or neuropsychiatric diseases is enriched in all presentations.
ALS, amyotrophic lateral sclerosis; bvFTD, behavioural variant FTD; FTD, frontotemporal dementia; nfvPPA, non- fluent variant primary progressive aphasia.
Figure 1 T1- weighted MR imaging of four affected C9orf72 expansion 
carriers, demonstrating the diversity of atrophy patterns that can be 
encountered. MRI scans were made at the time of the initial presentation; 
patients were between 55 and 62 years of age. (A) mild generalised 
cortical atrophy; (B) severe generalised cortical cerebral as well as 
cerebellar atrophy; (C) predominantly left- sided frontotemporal atrophy; 
(D) moderate symmetrical parietal atrophy as well as mild symmetrical 
frontotemporal atrophy.
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Motor neuron diseases
A C9orf72 expansion is identified in 20%–30% of familial and 
5% of apparently sporadic ALS cases.4 12 The median age at onset 
(57 years) in c9ALS is similar to that of ALS without a C9orf72 
expansion (non- c9ALS).13 14 The clinical phenotype of c9ALS 
covers the entire ALS spectrum, typically presenting with muscle 
weakness starting in one segment and spreading throughout the 
motor system (table 1). A bulbar onset of disease, character-
ised by early dysphagia and dysarthria, is seen in 30%–40% of 
c9ALS13 14 and appears to be more common than in non- c9ALS 
and may explain the shorter overall survival in c9ALS reported 
in some studies.13 14
Cognitive impairment and dementia, mostly of the bvFTD 
subtype, are more common in c9ALS than in non- c9ALS.15 
Accordingly, c9ALS patients show more extensive atrophy of 
non- motor areas of the frontal cortex than those with non- 
c9ALS. Although only 20% of ALS patients fulfil FTD diag-
nostic criteria, an additional 20% has some degree of cognitive 
impairment, usually in executive functioning, social cognition 
or language, and 10% shows behavioural changes. Screening 
instruments that are specifically designed to detect cognitive and 
behavioural symptoms in ALS, such as the Edinburgh Cognitive 
and Behavioural Screen, are increasingly used and may improve 
tailored patient care.
Other motor neuron diseases, including progressive muscular 
atrophy and primary lateral sclerosis, are rare in C9orf72 expan-
sion carriers.14
Psychiatric manifestations
Psychiatric symptoms occur at a much higher rate across the 
spectrum of C9orf72- related diseases than in non- c9FTD/
ALS. Psychotic features are reported in 20%–60% of c9FTD 
cases15 17 25 and include delusions and hallucinations in all sensory 
modalities, although somatic delusions are relatively common.15 
Other psychiatric manifestations include mood disorders, obses-
sive compulsive disorder and catatonia (table 1).25–27 Psychi-
atric symptoms are occasionally the initial presentation and 
sometimes occur several years before the emergence of more 
typical FTD or ALS symptoms.15 27 Misdiagnosis of a primary 
psychiatric disorder such as late- onset schizophrenia or late- 
onset bipolar disorder is not uncommon, especially in the case of 
(near- )normal neuroimaging.27
C9orf72 expansions in primary psychiatric disorders are 




Concomitant parkinsonism occurs more frequently in c9FTD/
ALS than in non- c9FTD/ALS, and is especially common in 
bvFTD patients, with up to 75% developing a variable degree 
of parkinsonism during the disease course.30 Symptoms include 
symmetrical or asymmetrical bradykinesia, rigidity, falls and gaze 
palsy, often with little or no tremor.30–32
An initial presentation of parkinsonism, ataxia or apraxia has 
probably led to an erroneous diagnosis of Parkinson’s disease 
(PD), progressive supranuclear palsy, corticobasal syndrome or 
multisystem atrophy in several expansion carriers.31 33 Some 
of these patients lacked typical FTD or ALS signs for several 
years after presentation.31–33 Parkinsonism in expansion carriers 
has been related to neuronal loss as well as TDP-43 and p62 
pathology reported in the basal ganglia in a few pathology- 
proven studies.34 35 Accordingly, while some cohorts of clinically 
diagnosed PD report occasional (<1%) expansions,33 36 across 
two large studies of autopsy- proven PD (pooled sample size 
>800 patients), just one expansion carrier was found who 
had both typical PD pathology as well as C9orf72- mediated 
pathology.34 37
HD-like syndrome
A C9orf72 expansion has been identified in up to 5% of patients 
with HD- like (HDL) syndrome, which is clinically indistinguish-
able from HD but without the typical CAG repeat expansion 
in the HTT gene, making it the most common genetic cause of 
HDL- syndromes.38 39 There is no evidence for a causal relation-
ship between C9orf72 and HD, but these findings are relevant for 
clinical practice as they demonstrate that expansion carriers may 
present with atypical signs including chorea, dystonia, tremor, 
rigidity, bradykinesia and myoclonus.39 Neuropathological data 
is needed to determine whether C9orf72- linked pathology in 
HD- related brain regions might underlie these unusual presenta-
tions. Remarkably, repeat expansions in HTT were recently iden-
tified in a small number of non- c9FTD/ALS patients, supporting 
a phenotypical and possibly etiological overlap between HD and 
FTD/ALS.
Other movement disorders
Other movement disorders in expansion carriers include cere-
bellar ataxia and a case with a clinical diagnosis of Creutzfeldt- 
Jakob disease.3 12 These cases probably represent misdiagnoses 
of unusual presentations of c9FTD/ALS and further highlight the 
diversity of the clinical spectrum.
Recommendations for genetic testing
Offering genetic testing for a C9orf72 repeat expansion is gener-
ally recommended in patients with concomitant FTD/ALS or 
familial FTD or ALS, but the best approach for seemingly sporadic 
FTD or ALS is still under debate.40 This is exemplified by two 
surveys published in 2017 which found that genetic testing is 
offered to 90% of familial ALS patients versus just 30%–50% of 
seemingly sporadic cases. The relatively frequent identification 
of expansions among seemingly sporadic cases, coupled with 
better availability of genetic testing and the promise of gene- 
targeted therapy, has led to an increasing tendency to consider 
genetic testing in all FTD (especially bvFTD) and ALS patients, 
regardless of family history.40 41 Importantly, although certain 
clinical features may prompt the clinician to suspect an under-
lying C9orf72 expansion (table 1), many c9FTD/ALS patients do 
not show distinctive features; relying on such features to select 
patients for genetic testing therefore carries the risk of missing 
expansion carriers.
While the overall frequency of a C9orf72 repeat expansion in 
psychiatric disease is very low, genetic testing should be consid-
ered in late- onset (>40 years) cases with cognitive decline, 
prominent cerebral or cerebellar atrophy, or a family history 
of FTD, ALS or psychiatric disease (table 1).41 Offering genetic 
testing has also been recommended for patients presenting with 
parkinsonism and concomitant upper or lower motor neuron 
symptoms or early neuropsychiatric or cognitive impairment.32
All patients and their families should receive genetic counsel-
ling prior to genetic testing, emphasising limitations of current 
testing methods and potential implications of test results.40 42 In 
many situations, coupling C9orf72 repeat expansion assays with 
multigene sequencing panels, which screen for the most common 
genetic mutations causing neurodegenerative disorders, is advis-
able considering the substantial overlap in symptomatology 
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between various mutations and the risk of mutations in multiple 
disease- causing genes .40
CLINICAL SIGNIFICANCE OF REPEAT LENGTH
Normal and pathological repeat length
There is no clear consensus on which C9orf72 repeat length is 
pathogenic. Most laboratories consider a repeat length of less 
than 20–30 in blood to be normal, while more than 200 repeats 
are very likely pathogenic.42 Small expansions (ie, up to 200 
repeats) represent a grey area in which some carriers develop 
symptoms, while others do not.43–45 The interpretation of small 
expansions presents a major challenge to clinical genetic coun-
selling and can have far- reaching consequences for affected 
families.42
Repeat length variation across and within tissues
Measuring C9orf72 repeat length, determining the threshold for 
pathogenic repeat length and identifying possible associations 
with clinical features is greatly complicated by instability of the 
expansion, which results in different repeat lengths across and 
within tissues of the same individual.3 8 43 44 46–48 Furthermore, 
expansion sizes in blood might not accurately reflect sizes in the 
CNS and should be interpreted cautiously.8 47 Direct comparisons 
of blood and brain tissue from the same individual demonstrate 
similar sizes in some subjects, but completely different sizes in 
others.8 47 48 This is illustrated by several cases with small expan-
sions in blood and long expansions in brain tissue.8 43 45 48 The 
interpretability of repeat lengths is also hampered by somatic 
instability in blood, resulting in big smears spanning a range of 
expansion sizes and possibly extra bands.3 47 49
In cell lines, expansion sizes should also be interpreted 
carefully. Cell lines usually contain fairly small expansions as 
compared with patient tissues.7 8 Additionally, due to their oligo-
clonal nature, they may demonstrate multiple concise bands, as 
shown for fibroblasts, lymphoblastoid cells, induced pluripotent 
stem cells (iPSCs), iPSC- derived neurons.7 8 49
The risk of false- negative genetic testing due to somatic insta-
bility in individuals with non- expanded alleles in blood is prob-
ably limited, since up to 30 repeats appear to be stable across 
tissues.43 48 Accordingly, no expansions were found in neural 
tissue of a small number of ALS patients with non- expanded 
alleles in blood.48 50
Clinico-pathological associations with expansion sizes
Although significant associations between clinical features and 
expansion size have been reported, findings are inconsistent, 
which might, to some extent, be explained by the substantial 
differences between tissues and subjects investigated. Some 
studies detected differences in expansion size between c9FTD 
and c9ALS,46 49 but others could not replicate these findings.3 8 48
Potential associations have been detected between repeat 
length in various tissues and age at symptom onset.3 7 8 47–49 51 
For example, one study reported a positive association between 
repeat length in the frontal cortex and age at onset in c9FTD.8 
At the same time, the C9orf72 expansion might further expand 
with increasing age.8 47 49 Age at sample collection and age at 
symptom onset are generally highly correlated, making it unclear 
whether longer expansions actually delay symptom onset or 
simply reflect increased repeat length as an individual ages. Since 
smaller repeat lengths have been observed in young presymp-
tomatic expansion carriers,47 49 the latter explanation seems 
plausible. Interestingly, associations with survival after onset 
suggest that smaller expansions might be beneficial.8 48 49
To replicate these associations, in- depth studies are necessary, 
taking into consideration differences between tissues, disease 
subgroups (c9FTD and/or c9ALS), age at collection and disease 
status (affected or unaffected). These studies could also reveal 
associations with pathological C9orf72- mediated features, such 
as levels of C9orf72 transcripts, RNA foci and DPR proteins.
Anticipation
A repeat expansion might lengthen in successive generations, 
which could lead to an earlier age at onset and/or more severe 
disease phenotype. This phenomenon—also known as antic-
ipation—has been reported in numerous repeat expansion 
disorders.5
Interestingly, an increase of roughly 1000 repeats from one 
generation to the next was described in a c9FTD family,44 sugges-
tive of anticipation. Moreover, in a subset of families, an earlier 
age at onset was observed in younger generations.1 52 Because 
Southern blots were not performed in most parent- offspring 
pairs included in these studies, it remains unclear whether or 
not reported differences in age at onset can be attributed to an 
increase in expansion size. One could postulate that individuals 
with a family history of FTD or ALS may seek medical atten-
tion sooner. Furthermore, a growing awareness of FTD and ALS 
in the general population and among clinicians as well as the 
availability of unified diagnostic criteria may lead to an earlier 
diagnosis. Besides, these findings could be (partially) driven by 
selection and/or recall bias.
Importantly, two recent studies actually provided evidence 
against anticipation in C9orf72- related diseases.47 51 These 
studies detected a reduction of the expansion size in succes-
sive generations, accounting for more than 50% of transmis-
sions.47 51 Intriguingly, contractions were frequently encountered 
in paternal transmissions, but rarely in maternal transmissions.47 
It should be noted that both studies were based on repeat lengths 
in blood which may not correlate with those in the brain. This is 
exemplified by a case report of an unaffected father with approx-
imately 70 repeats in blood, while his children harboured long 
expansions.53 Although this could indicate a jump from a premu-
tation to a disease- causing expansion in the next generation,53 
postmortem tissue of the father later revealed long expansions 
in his brain,45 stressing the importance of determining expan-
sion sizes in brain tissue. As such, to unravel whether anticipa-
tion contributes to C9orf72- linked diseases, large- scale studies 
focusing on brain tissue from multiple generations are needed.
DETECTING AND SIZING C9ORF72 REPEAT EXPANSIONS
Detection of C9orf72 repeat expansions with PCR-based 
approaches
The most commonly applied methods for detecting repeat expan-
sions are PCR- based approaches; a two- step protocol consisting 
of a fluorescent PCR fragment- length analysis followed by 
repeat- primed PCR is recommended (figure 2).1 A fluorescent 
PCR can specify the size of alleles within the wild- type range. If 
an individual has two alleles with a different number of repeats 
(eg, two repeats and five repeats), then two peaks are detected 
and no additional tests are required. If, however, a single peak 
is observed, then a repeat- primed PCR is warranted. A repeat- 
primed PCR is able to determine whether an apparently homo-
zygous individual carries two wild- type alleles with exactly the 
same number of repeats, or whether a wild- type allele is present 
in addition to an expanded allele that is too long for detection 
using a fluorescent PCR, in which case a characteristic stutter 
pattern is seen. Reactions should be repeated (eg, with more 
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DNA), when results are difficult to interpret. If the fluores-
cent PCR repeatedly fails (ie, does not reveal any peaks) in the 
presence of a stutter pattern on the repeat- primed PCR, then a 
homozygous expansion should be considered.
Importantly, an international study demonstrated that 6 out 
of 14 participating laboratories misclassified at least one sample 
when using a repeat- primed PCR alone.6 Given that the accuracy 
increased when both a fluorescent PCR and repeat- primed PCR 
were used,6 a two- step protocol is the preferred method to deter-
mine the presence or absence of a C9orf72 repeat expansion in 
a research setting. A subset of misclassifications should probably 
be attributed to the genomic complexity of the C9orf72 region. 
Sequence variants (eg, deletions and insertions) have been 
described downstream of the expansion.9 54 Depending on how 
the repeat- primed PCR has been designed and whether it has 
been thoroughly optimised, the presence of sequence variants 
might hamper the amplification of the expansion, and therefore, 
lead to a false negative repeat- primed PCR. Interestingly, it has 
been suggested that a downstream deletion lengthens the expan-
sion. A 10 bp deletion, for instance, removes several non- GC- 
bases, extending the GC- rich region with imperfect repeats.9 
Although this might be relevant for relatively small expansions, 
possibly decreasing stability of the repetitive area,9 one could 
doubt whether the addition of a few extra GC- bases to a long 
expansion will have a major effect.54 Regardless, these sequence 
variants should be taken into consideration since they may 
reduce the accuracy of the repeat- primed PCR
Detection and sizing of expanded C9orf72 repeats with 
Southern blotting
The gold standard to detect a C9orf72 repeat expansion is a 
Southern blot (figure 2). Results are highly consistent across 
laboratories,6 and Southern blotting should be used to confirm 
the presence of an expanded repeat, especially in a clinical 
setting. Moreover, Southern blotting can clarify whether an 
individual is heterozygous or homozygous for the expansion (ie, 
presence or absence of a band corresponding to the wild- type 
allele). As opposed to a repeat- primed PCR, Southern blotting is 
also capable of estimating the size of the expansion.
Various Southern blot protocols have been published to esti-
mate the size of expanded C9orf72 repeats using different restric-
tion enzymes and probes.3 8 46–49 Whether an area close to the 
expansion is targeted7 8 47 or the expansion itself,3 49 also affects 
the Southern blot: while probes that target the repeat frequently 
produce a strong signal, they can hybridise to GGGGCC- repeats 
in other areas (outside of the C9orf72 locus), and additionally, 
they may not visualise the wild- type allele, which is often used 
as an internal control that the Southern blot worked and which 
helps to elucidate whether someone is homozygous for the 
expansion.7 Even though Southern blotting can accurately deter-
mine the presence or absence of an expanded C9orf72 repeat 
and estimate its size, it is a time- consuming and technically chal-
lenging method requiring high- quality DNA.8
Detection of C9orf72 expansions with short-read sequencing
Several tools have been developed to detect a C9orf72 repeat 
expansion in PCR- free short- read whole- genome sequencing 
(WGS) data. The ExpansionHunter tool correctly identified 
all 212 C9orf72 expansion carriers in a cohort of over 3000 
ALS patients.55 Furthermore, a new version of this tool has been 
recently released that uses sequence graphs to handle complex 
loci. Despite encouraging results, it remains difficult to recon-
struct expansions based on short- read sequencing techniques.55
Employing long-read sequencing to assess sizes, interruptions 
and methylation patterns
Long- read sequencing techniques are a promising upcoming 
strategy to evaluate large repeat expansions. Popular plat-
forms have been developed by Oxford Nanopore Technologies 
(ONT) and Pacific Biosciences (PacBio). ONT’s nanopore tech-
nology measures changes in current as DNA passes through a 
nanopore,56 57 whereas PacBio’s single- molecule real- time tech-
nology measures fluorescence when nucleotides are added.56 58 
Figure 2 Stepwise approach for the detection of a C9orf72 repeat expansion. Fluorescent PCR fragment- length analysis is used to determine the number 
of alleles in the wild- type range. If a single peak is observed, then repeat- primed PCR is warranted to determine whether the individual carries two wild- type 
(WT) alleles with the exact same number of repeats, or whether a repeat expansion is present that is too long for detection by fluorescent PCR. if a repeat 
expansion is present, a characteristic stutter pattern is observed on repeat- primed PCR. especially in a clinical setting, it is recommended to confirm the 
presence of an expansion using southern blotting.
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In theory, long- read sequencing can span the entire C9orf72 
expansion, which facilitates reliable estimation of expansion 
sizes. Another major advantage of long- read sequencing is its 
ability to evaluate sequence content. It is possible, for example, 
to determine the presence of interruptions in C9orf72 repeat 
expansions,59 which is highly relevant since interruptions serve 
as disease modifiers in other repeat expansion disorders.5 
Furthermore, long- read sequencing provides the opportunity to 
examine the methylation status of expanded C9orf72 repeats.60 
Interestingly, while hypermethylation of the C9orf72 promoter 
is well documented, little is known about the methylation status 
of the expanded repeat itself in c9FTD/ALS patients. It has been 
suggested that the expansion is methylated; however, quanti-
tative assays have yet to be developed. Importantly, long- read 
sequencing requires high- molecular- weight genomic DNA, and 
DNA should be extracted using suitable protocols to ensure that 
the DNA, and therefore, the expansion, remains intact.
Several long- read sequencing technologies have been tested 
for C9orf72- linked diseases.59 60 Long- read WGS on ONT’s 
MinION platform and PacBio’s Sequel platform only yielded 
a relatively low number of reads covering the expanded allele. 
Newer CRISPR- Cas9- based enrichment strategies to specif-
ically examine the C9orf72 locus have considerably increased 
the yield.59 60 These proof- of- concept studies demonstrate the 
feasibility of long- read sequencing approaches, and further 
protocol optimisation is expected to improve their accuracy and 
efficiency, facilitating implementation of long- read sequencing 
in research and eventually in clinical settings.
OTHER POTENTIAL GENETIC DISEASE MODIFIERS
Besides repeat length, several other potential genetic disease 
modifiers have been identified, highlighting that a complex 
interplay of various genetic factors probably contributes to the 
phenotypic variability of the C9orf72 repeat expansion. For 
example, intermediate repeat expansions in ATXN2, a known 
risk factor for ALS, appear to be more common in c9ALS than 
in c9FTD, suggesting that they might drive the clinical pheno-
type towards ALS rather than FTD. Similarly, single- nucleotide 
polymorphisms (SNPs) in TMEM106B appear to protect specif-
ically against c9FTD, but not c9ALS, and two CpG- SNPs (ie, 
SNPs that affect DNA methylation patterns) at the C6orf10/
LOC101929163 locus are associated with age at symptom onset. 
The rare coexistence of pathogenic mutations in other FTD or 
ALS- associated genes, including GRN, MAPT, TBK1, TARDBP, 
SOD1 and FUS might in some cases act synergistically to influ-
ence disease severity and/or phenotypic features.
CONCLUSIONS AND FUTURE DIRECTIONS
The C9orf72 expansion is highly clinically heterogeneous, and 
clinicians need to be aware of the wide spectrum of associated 
symptoms in order to provide a timely diagnosis and manage-
ment and to select patients for clinical trials. Despite extensive 
research, the genetic basis of this heterogeneity remains poorly 
understood. Novel sequencing techniques that enable thorough 
assessment of the expansion size as well as its purity and meth-
ylation levels may reveal new associations with clinical features. 
The measurement and interpretation of repeat length is greatly 
complicated by the presence of somatic mosaicism, and a better 
understanding of repeat instability is needed to elucidate poten-
tial genotype–phenotype correlations as well as to determine the 
viability of therapeutic approaches aimed at stabilising repeat 
expansions.
The lack of consensus on clear cut- off values for pathogenicity 
poses a major challenge for clinical genetic counselling. Further 
research is also needed to determine whether intermediate repeat 
lengths have any clinical significance which, remarkably, have 
been associated with normal to upregulated C9orf72 expres-
sion,45 47 in contrast to the downregulation seen in patients with 
long expansions.
Besides repeat length, several other potential genetic determi-
nants have been identified. Possibly, multiple phenotypic modi-
fiers are present at the same time, concealing clear associations 
with each individual modifier. Future research into the various 
modifiers will be essential to predict the expected disease course, 
which in turn will be valuable both for patient management and 
for patient stratification in clinical trials.
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